About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma

 

Follicular Lymphoma >  ASCO 2012 - FL abstracts

Last update: 05/30/2012

Compiled from ASCO 2012 abstracts: Lymphoma | CLL

Comments or Questions?

  1. Effect of short-duration chemoimmunotherapy plus radioimmunotherapy on response rates in relapsed follicular lymphoma: A U.K. NCRI Lymphoma Group Study, CR UK/07/038. | 2012 ASCO Annual Meeting Abstracts

     
  2. A subgroup analysis of small lymphocytic and marginal zone lymphomas in the Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden indolent non-Hodgkin lymphoma. | 2012 ASCO Annual Meeting Abstracts

     
  3. Transformation of follicular lymphoma in the era of immunochemotherapy: A population-based study from British Columbia. | 2012 ASCO Annual Meeting Abstracts

     
  4. MLN9708, an investigational proteasome inhibitor, in patients (pts) with relapsed/refractory lymphoma: Emerging data from a phase I dose-escalation study. | 2012 ASCO Annual Meeting Abstracts

     
  5. Phase I/II study of investigational agent MLN8237 (alisertib) plus rituximab with or without vincristine in patients (pts) with relapsed/refractory (rel/ref) aggressive diffuse large B-cell lymphoma (DLBCL)/transformed follicular lymphoma (TFL). | 2012 ASCO Annual Meeting Abstracts

     
  6. High-dose chemotherapy followed by allogeneic stem cell transplantation in high-risk relapsed and refractory aggressive non-Hodgkin lymphoma: Results of a prospective study of the German high-grade non-Hodgkin lymphoma study group. | 2012 ASCO Annual Meeting Abstracts

     
  7. Association of tumor-associated macrophages of M2 subtype with outcome in follicular lymphoma. | 2012 ASCO Annual Meeting Abstracts

     
  8. Evaluation of MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, as a novel targeted agent with single-agent antitumor activity in mantle cell lymphoma (MCL) and Hodgkin lymphoma preclinical models. | 2012 ASCO Annual Meeting Abstracts

     
  9. R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL). | 2012 ASCO Annual Meeting Abstracts

     
  10. A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL). | 2012 ASCO Annual Meeting Abstracts

     
  11. Phase I trial of temsirolimus and lenalidomide in pts with rel/ref lymphomas. | 2012 ASCO Annual Meeting Abstracts

     
  12. Efficacy of ocaratuzumab (AME-133v) in relapsed follicular lymphoma patients refractory to prior rituximab. | 2012 ASCO Annual Meeting Abstracts

     
  13. A phase III randomized intergroup trial (S0016) comparing CHOP plus rituximab with CHOP plus iodine-131-tositumomab for front-line treatment of follicular lymphoma: Results of subset analyses and a comparison of prognostic models. | 2012 ASCO Annual Meeting Abstracts

     
  14. CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. | 2012 ASCO Annual Meeting Abstracts

     
  15. Prognostic value of etoposide area under the curve (AUC) in lymphoma patients treated with BEAM regimen and ASCT: Multicenter study of Groupe d'Etudes des Lymphomes de l'Adulte (GELA). | 2012 ASCO Annual Meeting Abstracts

     
  16. An update on gemcitabine, rituximab, and oxaliplatin in combination for relapsed/refractory non-Hodgkin lymphomas. | 2012 ASCO Annual Meeting Abstracts

     
  17. R-ICE versus R-ESHAP for salvage therapy in aggressive B-cell non-Hodgkin lymphoma. | 2012 ASCO Annual Meeting Abstracts

     
  18. A single-institution experience with the hyper-CVAD regimen in aggressive NHL. | 2012 ASCO Annual Meeting Abstracts

     
  19. Comparison of clinical parameters and survival in Vietnam era (V) versus non-Vietnam era (non-V) veterans with non-Hodgkin lymphoma (NHL). | 2012 ASCO Annual Meeting Abstracts
  20. A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). | 2012 ASCO Annual Meeting Abstracts

     
  21. Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory b-cell non-Hodgkin's lymphoma (NCT00796731). | 2012 ASCO Annual Meeting Abstracts

     
  22. The impact of race, age, and sex in follicular lymphoma (FL): A comprehensive SEER analysis in the pre- and post-rituximab (R) eras. | 2012 ASCO Annual Meeting Abstracts

     
  23. A phase II study of PXD101 (belinostat) in relapsed and refractory aggressive B-cell lymphomas (rel/ref ABCL): SWOG S0520. | 2012 ASCO Annual Meeting Abstracts

     
  24. Effect of sunlight exposure on survival in patients with lymphoma: Results from the prospective Singapore Lymphoma Study. | 2012 ASCO Annual Meeting Abstracts

     
  25. LR-CD: Lenalidomide combination therapy for untreated low-grade B-cell NHL. | 2012 ASCO Annual Meeting Abstracts

     
  26. Phase I/II study of MEDI-551, a humanized monoclonal antibody targeting CD19, in subjects with relapsed or refractory advanced B-cell malignancies. | 2012 ASCO Annual Meeting Abstracts

     
  27. Phase I trial of fenretinide (4-HPR) intravenous emulsion in hematologic malignancies: A California Cancer Consortium study (PhI-42). | 2012 ASCO Annual Meeting Abstracts

     
  28. Pharmacokinetics (PK) of bendamustine when administered in combination with rituximab in patients with non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL). | 2012 ASCO Annual Meeting Abstracts

     
  29. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. | 2012 ASCO Annual Meeting Abstracts

     
  30. High affinity CD3 RECRUIT TandAb for T cell-mediated lysis of CD19+ tumor B cells. | 2012 ASCO Annual Meeting Abstracts


     
  31. Rituximab hypersensitivity reactions (HSR): Predictors of recurrent and severe reactions based on severity of reaction, NHL histologic subtype, and burden of disease. | 2012 ASCO Annual Meeting Abstracts

     
  32. Widespread use of complementary and alternative medicine (CAM) among non-Hodgkin lymphoma (NHL) survivors. | 2012 ASCO Annual Meeting Abstracts
     


 

 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright 2004,  All Rights Reserved.